JPRN-jRCT2080221731
Unknown
Phase 3
Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study with an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment with Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects with Severe Alzheimer's Disease
ConditionsSevere Alzheimer's Type Dementia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Severe Alzheimer's Type Dementia
- Sponsor
- Eisai Co., Ltd.
- Enrollment
- 330
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnosis: diagnostic evidence of probable AD consistent with DSM\-IV\-TR 290\.00 or 290\.10
- •2\. MMSE \<\- 12 and \-\> 1 inclusive, at Screening
- •3\. SIB \<\- 90 and \-\> 10 at both Screening and Baseline
- •4\. No evidence of focal disease to account for dementia on any cranial image (MRI or CT).
- •5\. Outpatients (patients in nursing homes are eligible)
- •6\. The subject must have a caregiver who will provide informed consent separately for his/her own participation in the study, who will have regular contact with the subject
- •7\. Stable donepezil dose of 10 mg, taken as a single, daily dose for \-\> 3 months prior to the Screening visit
- •8\. Subjects who can swallow hole tablets, as tablets should not be broken or crushed
- •9\. Comorbid medical conditions must be clinically stable prior to Screening unless otherwise specified
- •10\. Written informed consent will be obtained from the subject(if possible) or from the subject's legal guardian or other representative (according to Japanese regulations as appropriate) prior to beginning screening activities
Exclusion Criteria
- •1\. Subjects with a known history of disorders that affect cognition or the ability to assess cognition but are distinguishable from AD
- •2\. Subjects with dementia complicated by other organic disease or AD with delirium
- •3\. Known hypersensitivity to donepezil or piperidine derivatives, or to any of the excipients in the study drug formulation
- •4\. Patients who are expected to live in a nursing home within 24 weeks after randomization (eligible if temporary)
- •5\. Use of any prohibited prior or concomitant medications. Memantine will be allowed if taken at prescribed doses that are less than or equal to 20 mg/day, provided that the dose has been stable for at least 6 months prior to Screening
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 19.0Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-000768-27-HUBayer AG7,000
Active, not recruiting
Phase 1
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)EUCTR2013-000768-27-GRBayer HealthCare AG7,000
Active, not recruiting
Phase 1
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 17.0Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-000768-27-SEBayer HealthCare AG7,000
Active, not recruiting
Phase 1
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 18.1 Level: PT Classification code 10014498 Term: Embolic stroke System Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-000768-27-PTBayer HealthCare AG7,213
Active, not recruiting
Phase 1
Rivaroxaban versus Aspirin in secondary prevention of stroke and prevention of systemic embolism in patients with recent embolic stroke of undetermined source (ESUS)Embolic stroke of undetermined source (ESUS)MedDRA version: 19.0Level: PTClassification code 10014498Term: Embolic strokeSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2013-000768-27-DKBayer AG7,000